SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02511288

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Liquid Biopsies in Patients With Advanced Non-small Cell Lung Cancer

The goal of this project is to characterize the genetic profile of patients with advanced stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies

NCT02511288 Carcinoma, Non-Small-Cell Lung
MeSH: Carcinoma, Non-Small-Cell Lung
HPO: Non-small cell lung carcinoma


Primary Outcomes

Description: Technique: ddPCR + targeted NGF, whole exome sequencing

Measure: Identification of the genetic profile in advanced or metastatic NSCLC patients using liquid biopsies (circulating tumoral DNA)

Time: 5 years

Secondary Outcomes

Description: Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Identification of genetic biomarkers (or molecular profiles) having a potential predictive value in the treatments response

Time: 5 years

Description: Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Detection of the ALK and ROS1 genes translocations in the circulating DNA

Time: 5 years

Description: Correlation between mutated allelic fractions or expression's modification with the treatment response. Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of the liquid biopsies role in the tumoral monitoring

Time: 5 years

Description: Correlation between transcriptomic and genomic factors and response to immunotherapy. Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of genomic and transcriptomic factors detectable in the plasma, associated to the immunotherapy response

Time: 5 years

Description: Techniques: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of the spatial and temporal tumor heterogeneity under targeted therapy treatment

Time: 5 years

Description: Correlation between miRNAS expression in plasma and treatment's efficacy. Techniques: miRNAs profiling using HTG technology

Measure: Evaluation of the miRNAs' expression in plasma as an epigenetic factor associated to treatments response

Time: 5 years

Description: Single cell isolation technology

Measure: Circulating tumoral cells isolation and analysis to determine the role of non-genomic and/or phenotypic factors in the treatments response.

Time: 5 years

Description: Technique: ddPCR + targeted NGF, whole exome sequencing

Measure: Evaluation of the resistance mechanisms to targeted therapies

Time: 5 years

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 T790M

It is presently used in routine for detecting the EGFR mutations at diagnosis as well as for searching EGFR T790M mutation for resistant patients. --- T790M ---



HPO Nodes


HPO:
Non-small cell lung carcinoma
Genes 2
TP53 BAP1